Over 150 Total Lots Up For Auction at One Location - CA 05/31

Pie Medical Imaging announces 500th patient in the FAST III clinical trial

Press releases may be edited for formatting or style | January 20, 2023 Business Affairs Cardiology
MAASTRICHT, Netherlands, Jan. 20, 2023 /PRNewswire/ -- Pie Medical Imaging, a global leader in cardiac imaging, announced the 500th patient inclusion in the FAST III, a multi-center randomized clinical trial, which investigates the use of angiography-based vessel fractional flow reserve (CAAS vFFR) in patients undergoing coronary revascularization procedures. In this trial, a CAAS vFFR guided strategy is compared to a FFR guided strategy to guide coronary revascularization. The primary endpoint is a composite of all-cause death, any myocardial infarction, or any revascularization at 1-year post-randomization.

The trial, led by Dr. Joost Daemen (cardiologist at the Thoraxcenter at the Erasmus University Medical Center, Rotterdam, The Netherlands), is an investigator initiated international, multi-center randomized, non-inferiority trial. 500 patients are enrolled by hospitals with great expertise in coronary physiology at 25 sites across Europe in The Netherlands, Germany, Spain, Ireland, United Kingdom, Italy, and France. A total of 35 sites will be recruited with the final aim to include 2,228 patients by the end of the year.

CAAS vFFR (Pie Medical Imaging, Maastricht, The Netherlands) is an angio-based FFR software suite to enable physiological assessment of intermediate coronary stenosis without the need of a pressure wire and adenosine. The vFFR value can be calculated with solely two angiographic projections and the aortic root pressure. This vFFR has a high correlation and diagnostic accuracy compared with wire based invasive FFR and NHPR measurements and the vFFR results are proven to be highly reproducible.

"The FAST III trial, together with several other studies currently being performed with CAAS vFFR, will increase the scientific body of evidence showing that the CAAS vFFR software is an excellent alternative to invasive wire-based physiological measurements," said Rene Guillaume, Managing Director PMI.

The trial is funded by research grants from Pie Medical Imaging (Maastricht, the Netherlands) and Siemens Healthineers (Erlangen, Germany). The study is sponsored by ECRI (European Cardiovascular Research Institute, Rotterdam-the Netherlands). Cardialysis (Rotterdam, The Netherlands) is responsible for trial services including trials management and Core Laboratory activities.

About Pie Medical Imaging
Pie Medical Imaging BV is a world leader in analysis and visualization of cardiovascular images. In Maastricht (The Netherlands), it hosts the global sales for the CAAS and 3mensio product lines. PMI and 3mensio Medical Imaging are part of the Esaote Group, leader in the biomedical equipment sector. More information about PMI is available at www.piemedicalimaging.com.

Back to HCB News

You Must Be Logged In To Post A Comment